<DOC>
	<DOCNO>NCT01497041</DOCNO>
	<brief_summary>1 . Goals The primary goal phase II trial : evaluate response rate combination chemotherapy docetaxel oxaliplatin patient stage IIIB/IV non-adenocarcinoma , non-small cell lung cancer ( NSCLC ) second-line treatment Secondary goal : evaluate treatment-related toxicity combination , investigate progression-free survival ( PFS ) overall survival ( OS ) population 2 . Design The proposed clinical trial open label , non-comparative , multicenter phase II trial accord two stage test design Simon two-stage testing procedure</brief_summary>
	<brief_title>A Phase II Clinical Trial Docetaxel , Oxaliplatin Combination Chemotherapy Patients With Stage IIIB/IV Non-adenocarcinoma , Non-small Cell Lung Cancer ( NSCLC ) Second-line Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Large Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Patients diagnose nonadenocarcinoma , nonsmall cell carcinoma lung histologically cytologically 2 . Patients must ≥ 18 year old age 3 . ECOG performance status ≤ 1 4 . Estimated life expectancy 3 month 5 . Treatment one prior chemotherapy 6 . At least one lesion measure imaging ( CT/MRI ) accord Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) 7 . Adequate bone marrow function ( absolute neutrophil count [ ANC ] ≥ 1,500/µL , hemoglobin ≥ 9.0 g/dL [ correction transfusion acceptable ] , platelet ≥ 100,000/µL ) 8 . Adequate kidney function ( serum creatinine &lt; 1.5 x upper limit normal [ ULN ] ) 9 . Adequate liver function ( serum total bilirubin &lt; 1.5xULN ; serum transaminases level &lt; 2.5xUNL ) 10 . Provision fully inform consent prior study specific procedures 1 . Pregnant breastfeed woman woman childbearing potential employ adequate contraception 2 . Patients receive prior chemotherapy include paclitaxel docetaxel 3 . Patients second primary cancer ( except , adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease ≥5 year ) 4 . Patients defect central nervous system ( CNS ) psychiatric disorder CNS metastases 5 . Other serious illness medical condition A. Clinically significant cardiac disease ( uncontrolled congestive heart disease despite treatment [ NYHA class III IV ] , symptomatic coronary artery disease , unstable angina myocardial infarction , conduction abnormality like grade 2 AV block , serious arrhythmia need medication , uncontrolled hypertension ) within 6 month prior study entry B. Liver cirrhosis ( ≥ ChildPugh class B ) C. History significant neurologic psychiatric disorder include dementia seizure D. Active uncontrolled infection E. Other serious underlie medical condition could impair ability patient participate study 6 . Concomitant administration experimental drug investigation , concomitant chemotherapy , hormonal therapy , immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>